|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
1.57/2.18
|
Enterprise Value
3.00B
|
Balance Sheet |
Book Value Per Share
6.51
|
Cash Flow |
Cash Flow Yield
0.09
|
Income Statement |
Total Revenue
491.73M
|
Operating Revenue Per Share
2.86
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). |